Table 5.
Univariate analysis of timing of BRAF inhibitor on local control for metastases treated with GK SRS.
| Timing of BRAF inhibitor use | N | # events | Local control at 1 year (%) | Median months to failure | Relative risk of failure (95% CI) | p-value |
|---|---|---|---|---|---|---|
| After GK SRS | 11 | 4 | 64 | 7.7 | 1.0 | 0.71 |
| Before and after GK SRS | 16 | 2 | 87 | 1.6 | 2.0 (0.2–17.8) | |
| Before GK SRS | 2 | 1 | 50 | 2.7 | 0.7 (0.1–4.0) |